Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program
Open Access
- 8 February 2026
- journal article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (6) , 1075-1085
Abstract
Introduction: Rapid symptom relief is an important consideration for patients with ulcerative colitis (UC) experiencing a flare. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. We evaluated patient-reported symptomatic improvement from patients in the ELEVATE UC program. Methods: This study was a post-hoc analysis of pooled daily e-diary data from patients with moderately to severely active UC receiving etrasimod or placebo in the phase III ELEVATE UC 52 and ELEVATE UC 12 trials. During the 12-week induction periods, patients self-reported stool frequency and rectal bleeding on days 1-28. Daily symptomatic response and symptomatic remission were calculated (partial modified Mayo Score). Results: Overall, 787 patients (527 receiving etrasimod, 260 placebo) were included in the analysis. Etrasimod-treated patients had statistically significantly higher rates of symptomatic response and symptomatic remission during the first 28 days of therapy, with adjusted differences (95% CIs) reaching statistical significance from day 2 (5.6% [0.8-10.3], P = .022) to day 11 (4.7% [0.4-9.0], P = .034), respectively. In patients naïve to biologic/Janus kinase inhibitor therapy, symptomatic response was statistically significantly improved with etrasimod vs placebo from day 3 (8.9% [2.3-15.5], P = .008). Symptomatic improvement rates were similar with and without concomitant corticosteroid use. Conclusions: In this post-hoc analysis, improvements in UC symptoms occurred in patients receiving etrasimod vs placebo from as early as day 2. These findings indicate a rapid onset of symptomatic effect with etrasimod treatment for moderately to severely active UC. ClinicalTrials.gov numbers: NCT03945188, NCT03996369.Keywords
Funding Information
- Pfizer
This publication has 20 references indexed in Scilit:
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative ColitisGastroenterology, 2024
- Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 TrialsJournal of Crohn's and Colitis, 2024
- Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesThe Lancet, 2023
- Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysiseClinicalMedicine, 2023
- Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction TreatmentClinical Gastroenterology and Hepatology, 2022
- What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference StudyJournal of Crohn's and Colitis, 2022
- ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical TreatmentJournal of Crohn's and Colitis, 2021
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDGastroenterology, 2021
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2019
- Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based studyDigestive and Liver Disease, 2016